Midazolam (Nayzilam) vs Staccato Alprazolam

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Epilepsy

Shared mechanism: GABA-A receptor · full Epilepsy pipeline

Midazolam (Nayzilam)

Marketed by UCB

Approved in Epilepsysmall molecule
Reliable signal

NCT01390220 · Phase 3 · terminated

This was a randomized, triple-blind, placebo-controlled trial in 201 patients, and the primary outcome, control of a seizure cluster with no recurrence, was reached significantly more often with midazolam than with placebo (72 of 134 patients vs 23 of 67, p=0.011).

Reported efficacy

Participants Who Met the Criteria for Treatment Success After Administration of the Double-blind Dose in the Comparative Phase (CP) (6 hours): Participants Who Met the Criteria for Treatment Success After Administration of the Double-blind Dose in the Comparative Phase (CP) (6 hours): USL261 CP 72/134 vs Placebo CP 23/67 (met)

Result source: NCT01390220

Staccato Alprazolam

Developed by UCB and partners

Phase 3 in Epilepsysmall molecule
Reliable signal

NCT03478982 · Phase 2 · completed

The study randomized participants to Staccato alprazolam or matching placebo and was described as quadruple-blind, with 156 participants enrolled and 38, 38, and 40 participants in the evaluable 1.0-mg, 2.0-mg, and placebo groups, respectively. Its primary clinical endpoint—seizure cessation within 2 minutes without recurrence for 2 hours—was statistically significantly better with both alprazolam doses than with placebo.

Next expected readout: March 2027 · NCT05077904 (registry estimate)

Reported efficacy

Percentage of Participants in Each Treatment Group Achieving Seizure Activity Cessation Within 2 Minutes and no Recurrent Seizure Within 2 Hours (2 hours post-dosing on dosing day): 1.0 mg: 65.8% vs 42.5% placebo (difference 23.3 percentage points; p=0.0392; 95% CI 1.8 to 44.8); 2.0 mg: 65.8% vs 42.5% placebo (difference 23.3 percentage points; p=0.0392; 95% CI 1.8 to 44.8) (met)

Result source: NCT03478982

Results for Epilepsy

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

These assets measured different things. Their trials share no endpoint in common, so no efficacy row can be built. That is a property of the programmes rather than a gap in the record: each asset's own reported endpoints are listed below.

Key endpointMidazolam (Nayzilam)Staccato Alprazolam
Seizure frequency, % change—Not reported—Trial running · NCT05076617
50% responder rate—Not reported—Trial running · NCT05076617
Seizure freedom54.8% vs 38.7%+16.1 vs placebowk 0.04 · n 31NCT01999777—Trial running · NCT05076617

Seizure frequency, % change

Midazolam (Nayzilam)
—Not reported
Staccato Alprazolam
—Trial running · NCT05076617

50% responder rate

Midazolam (Nayzilam)
—Not reported
Staccato Alprazolam
—Trial running · NCT05076617

Seizure freedom

Midazolam (Nayzilam)
54.8% vs 38.7%+16.1 vs placebowk 0.04 · n 31NCT01999777
Staccato Alprazolam
—Trial running · NCT05076617
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Midazolam (Nayzilam): 4 of 4 rows · Staccato Alprazolam: 3 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricMidazolam (Nayzilam)Staccato Alprazolam
Dropout rate
—5 mg + 5 mga
NCT01390220 · Phase 3 · Epilepsy · phase 3
show 4 more results
—5 mg only
NCT01390220 · Phase 3 · Epilepsy · phase 3
—USL261 CP
NCT01390220 · Phase 3 · Epilepsy · phase 3
31.2%USL261 TDP
NCT01390220 · Phase 3 · Epilepsy · phase 3
0%
NCT01999777 · Phase 3 · monotherapy
0%2.0 mgb
NCT03478982 · Phase 2
show 2 more results
0%1.0 mg
NCT03478982 · Phase 2
0%1.0 mg
NCT03478982 · Phase 2
Discontinued due to AEs
—5 mg + 5 mga
NCT01390220 · Phase 3 · Epilepsy · phase 3
show 4 more results
—5 mg only
NCT01390220 · Phase 3 · Epilepsy · phase 3
—USL261 CP
NCT01390220 · Phase 3 · Epilepsy · phase 3
5.8%USL261 TDP
NCT01390220 · Phase 3 · Epilepsy · phase 3
—
NCT01999777 · Phase 3 · monotherapy
—2.0 mgb
NCT03478982 · Phase 2
show 2 more results
—1.0 mg
NCT03478982 · Phase 2
—1.0 mg
NCT03478982 · Phase 2
Serious AEs
0%5 mg + 5 mga
NCT01390220 · Phase 3 · Epilepsy · phase 3
show 4 more results
0%5 mg only
NCT01390220 · Phase 3 · Epilepsy · phase 3
—USL261 CP
NCT01390220 · Phase 3 · Epilepsy · phase 3
0.7%USL261 TDP
NCT01390220 · Phase 3 · Epilepsy · phase 3
0%
NCT01999777 · Phase 3 · monotherapy
0%2.0 mgb
NCT03478982 · Phase 2
show 2 more results
2.6%1.0 mg
NCT03478982 · Phase 2
0%1.0 mg
NCT03478982 · Phase 2
Most frequent reported AEs
5 mg + 5 mga
nasal discomfort 16.3% (placebo 7.3%)
somnolence 9.3% (placebo 9.8%)
throat irritation 7% (placebo 2.4%)
NCT01390220 · Phase 3 · Epilepsy · phase 3
show 3 more results
5 mg only
somnolence 9.9% (placebo 9.8%)
headache 6.6% (placebo 0%)
nasal discomfort 5.5% (placebo 7.3%)
NCT01390220 · Phase 3 · Epilepsy · phase 3
nasal discomfort 16.1% (placebo 7.3%)
somnolence 9.6% (placebo 9.8%)
lacrimation increased 6.8% (placebo 2.4%)
NCT01390220 · Phase 3 · Epilepsy · phase 3
nasal discomfort 16.1% (placebo 16.1%)
nausea 9.7% (placebo 3.2%)
throat irritation 9.7% (placebo 9.7%)
NCT01999777 · Phase 3 · monotherapy
2.0 mgb
cough 18.4% (placebo 0%)
dysgeusia 10.5% (placebo 2.5%)
somnolence 10.5% (placebo 2.5%)
NCT03478982 · Phase 2
show 2 more results
1.0 mg
somnolence 18.4% (placebo 2.5%)
dysgeusia 15.8% (placebo 2.5%)
cough 10.5% (placebo 0%)
NCT03478982 · Phase 2
1.0 mg
cough 12.5% (placebo 0%)
dysmenorrhoea 12.5% (placebo 0%)
gastroenteritis viral 12.5% (placebo 0%)
NCT03478982 · Phase 2

Notes

  1. aPopulation comparability has not been reviewed for 1 of these studies.
  2. bPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Midazolam (Nayzilam)

Seizure Cluster Treatment Success 53.7% (n=134) vs 34.3% (n=67) placebo
event count · % of participants
NCT01390220 · Phase 3 · Epilepsy · phase 3 · converted to % from 72 Participants as posted
Seizure Recurrence 4h 38.1% (n=134) vs 59.7% (n=67) placebo
event count · % of participants
NCT01390220 · Phase 3 · Epilepsy · phase 3 · converted to % from 51 Participants as posted
Seizure Recurrence 24 h 37.3% (n=134) vs 46.3% (n=67) placebo
event count · % of participants
NCT01390220 · Phase 3 · Epilepsy · phase 3 · converted to % from 50 Participants as posted
Time to Next Seizure NA vs 12.1 placebo hours
absolute value · hours
NCT01390220 · Phase 3 · Epilepsy · phase 3
Seizure-free 54.8% (n=31) vs 38.7% (n=31) placebo @ 0.04wk
responder rate · % of participants
NCT01999777 · Phase 3 · monotherapy · converted to % from 17 Participants as posted
Time to First Seizure NA vs 3.9 placebo hours
absolute value · hours
NCT01999777 · Phase 3 · monotherapy

Staccato Alprazolam

Seizure Cessation 2min no Recurrence 2 h 65.8% (n=38) vs 42.5% (n=40) placebo @ 0.01wk2.0 mg
responder rate · % of participants
NCT03478982 · Phase 2
show 2 more results
62.5% (n=8) vs 42.5% (n=40) placebo @ 0.01wk1.0 mg
NCT03478982 · Phase 2
65.8% (n=38) vs 42.5% (n=40) placebo @ 0.01wk1.0 mg
NCT03478982 · Phase 2
Rescue Medication Use 7.9% (n=38) vs 7.5% (n=40) placebo @ 0.01wk2.0 mg
responder rate · % of participants
NCT03478982 · Phase 2
show 2 more results
0% (n=8) vs 7.5% (n=40) placebo @ 0.01wk1.0 mg
NCT03478982 · Phase 2
15.8% (n=38) vs 7.5% (n=40) placebo @ 0.01wk1.0 mg
NCT03478982 · Phase 2
Secondary Generalization 0% (n=38) vs 0% (n=40) placebo @ 0.14wk2.0 mg
responder rate · % of participants
NCT03478982 · Phase 2
show 2 more results
12.5% (n=8) vs 0% (n=40) placebo @ 0.14wk1.0 mg
NCT03478982 · Phase 2
0% (n=38) vs 0% (n=40) placebo @ 0.14wk1.0 mg
NCT03478982 · Phase 2

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Midazolam (Nayzilam)'s landscape · Staccato Alprazolam's landscape